Sort
40,608 grants matching “prostate cancer”
Enhancement of BB2r-Targeted Radiotherapy for Prostate Cancer Utilizing Hypoxia-S
$312,288Jered C Garrison · University Of Nebraska Medical Center · R01 · FY2018 · CA
EWS/FLI AND ITS TARGETS IN EWING'S SARCOMA
$312,288Stephen L Lessnick · University Of Utah · R01 · FY2010 · CA
An inevitable mechanism of resistance to androgen-directed therapy
$312,288Yan Dong · Tulane University Of Louisiana · R01 · FY2014 · CA
The role of IL-17 in prostate cancer
$312,288Zongbing You · Tulane University Of Louisiana · R01 · FY2016 · CA
Enhancement of BB2r-Targeted Radiotherapy for Prostate Cancer Utilizing Hypoxia-S
$312,288Jered C Garrison · University Of Nebraska Medical Center · R01 · FY2014 · CA
Enhancement of BB2r-Targeted Radiotherapy for Prostate Cancer Utilizing Hypoxia-S
$312,288Jered C Garrison · University Of Nebraska Medical Center · R01 · FY2017 · CA
An inevitable mechanism of resistance to androgen-directed therapy
$312,288Yan Dong · Tulane University Of Louisiana · R01 · FY2017 · CA
Enhancement of BB2r-Targeted Radiotherapy for Prostate Cancer Utilizing Hypoxia-S
$312,288Jered C Garrison · University Of Nebraska Medical Center · R01 · FY2015 · CA
Progression/Oncogene Induced Prostate Cancer
$312,288Baylor College Of Medicine · R01 · FY2002 · CA
DOUBLE-TARGETED MACROMOLECULAR THERAPEUTICS FOR THE TREATMENT OF PROSTATE CANCER
$312,288Jindrich N. Kopecek · University Of Utah · R01 · FY2009 · CA
A Role of Novel Serpin Maspinin Prostate Tumor/Bone Interaction
$312,288Shijie Sheng · Wayne State University · R01 · FY2009 · CA
A Role of Novel Serpin Maspinin Prostate Tumor/Bone Interaction
$312,288Shijie Sheng · Wayne State University · R01 · FY2010 · CA
Progression/Oncogene Induced Prostate Cancer
$312,288Baylor College Of Medicine · R01 · FY2005 · CA
An inevitable mechanism of resistance to androgen-directed therapy
$312,288Yan Dong · Tulane University Of Louisiana · R01 · FY2018 · CA
DOUBLE-TARGETED MACROMOLECULAR THERAPEUTICS FOR THE TREATMENT OF PROSTATE CANCER
$312,288Jindrich N. Kopecek · University Of Utah · R01 · FY2010 · CA
The role of XMRV, a newly discovered human retrovirus, in cancer pathogenesis
$312,288Ila R Singh · University Of Utah · R01 · FY2010 · CA
An inevitable mechanism of resistance to androgen-directed therapy
$312,288Yan Dong · Tulane University Of Louisiana · R01 · FY2015 · CA
Enhancement of BB2r-Targeted Radiotherapy for Prostate Cancer Utilizing Hypoxia-S
$312,288Jered C Garrison · University Of Nebraska Medical Center · R01 · FY2016 · CA
Progression/Oncogene Induced Prostate Cancer
$312,288Baylor College Of Medicine · R01 · FY2004 · CA
Progression/Oncogene Induced Prostate Cancer
$312,288Baylor College Of Medicine · R01 · FY2003 · CA
The role of IL-17 in prostate cancer
$312,288Zongbing You · Tulane University Of Louisiana · R01 · FY2017 · CA
A Role of Novel Serpin Maspinin Prostate Tumor/Bone Interaction
$312,288Shijie Sheng · Wayne State University · R01 · FY2008 · CA
Molecular Imaging of Chemokine Receptor Signaling
$312,256Gary D Luker · University Of Michigan At Ann Arbor · R01 · FY2010 · CA
GLUCOCORTICOIDS &VITAMIN D: ROLE IN ANTI-TUMOR EFFECTS
$312,255Roswell Park Cancer Institute Corp · R01 · FY2002 · CA
Phase II Clincal Trial of Purified Isofavones in Prostate Cancer: Comparing Safet
$312,250Nagi B Kumar · University Of South Florida · P20 · FY2011 · MD